EGFR and HER2 Expression in Cervical Cancer
Author Information
Author(s): Shen Li, Shui Yongjie, Wang Xiaojia, Sheng Liming, Yang Zhengyan, Xue Danfeng, Wei Qichun
Primary Institution: Zhejiang University School of Medicine
Hypothesis
Are EGFR and HER2 suitable targets for clinical diagnosis and therapy in cervical cancer?
Conclusion
EGFR expression is common and stable during cervical cancer metastasis, while HER2 is not a viable target for treatment.
Supporting Evidence
- EGFR overexpression was found in 64% of primary cervical tumors.
- 60% of lymph node metastases also showed EGFR overexpression.
- None of the primary tumors or lymph node metastases expressed HER2 protein.
Takeaway
This study looked at how two proteins, EGFR and HER2, behave in cervical cancer. It found that EGFR is often present and stays the same in cancer spread, but HER2 is not useful for treatment.
Methodology
Immunohistochemical analysis of EGFR and HER2 expression in primary cervical cancers and lymph node metastases.
Limitations
The study is limited by the small sample size.
Participant Demographics
{"age":{"median":48,"range":"29-72"},"gender":"female","cancer_type":"squamous cell carcinoma"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website